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This paper sheds light on the product cycle and neotechnology theories of trade in the 
context of generic pharmaceuticals. The paper studies the export performance of 177 
Indian pharmaceutical firms for the post-liberalization period 1991-2004. The results 
indicate that technology proxied by foreign patent rights has a positive impact on exports. 
This suggests that developing countries with innovation skills for process innovations are 
capable of penetrating international markets in the later stages of the product cycle by 
using patents, which were the barriers to trade in the early stages of the product cycle. 
Thus, Indian pharmaceutical firms adept at reverse-engineering of brandname drugs have 
an opportunity to enter the global generic market for off-patent drugs.   
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 1. Introduction 
In pharmaceuticals and many other industries, technology has emerged as one of the 
most important factors determining international trade flows. The value of goods and 
services that countries trade increasingly resides in their intellectual content, technology, 
R&D and human creativity that is sought to be protected by intellectual property rights 
(IPRs). Thus, under the new international order advocated by the World Trade 
Organization (WTO), IPRs are fast emerging as a “global currency for power” 
(Zimmerman and Dunlop, 1994). For the first time in international law, the Agreement on 
Trade Related Aspects of Intellectual Property Rights (TRIPs) sets out the procedures 
that governments must provide under their domestic law so that IPRs can be effectively 
enforced. Particularly for pharmaceuticals, TRIPs requires that developing countries 
should provide for both product and process patents
1 with a patent term of 20 years by 
January 2005. 
The pharmaceutical industry in India has been a success story in the development of 
an indigenous, self-reliant industry. The Indian Patent Act 1970 provided for only process 
patents and abolished product patents for pharmaceuticals under that Act. The Act also 
reduced the patent term from 16 to seven years. Thus, Indian firms were free to use a 
different process of production to make the same products developed by foreign MNCs. 
However, due to rapid policy changes in India, beginning with the liberalization of the 
economy in 1991 and the establishment a new trading regime with the setting up of the 
WTO in 1995, the pharmaceutical industry is at crossroads preparing itself for greater 
competition domestically and internationally because under the old regime it was 
                                                 
1 Product patents are granted for a new innovation whereas process patents are granted for a new way of 
manufacturing a given product. profitable for the Indian pharmaceutical industry to produce cheaper generic versions of 
brandname drugs. The main competitive advantage of Indian firms lies in their ability to 
do “reverse engineering”
2 and speedily bring down costs through process development 
for generic drugs.  
In fact, India was a leading bulk drug exporter in the international market in the late 
eighties but lost that position to China as it started undercutting India’s prices and 
entering the world market. Now after a dull phase, Indian pharmaceutical firms are 
reviving as quality exporters of bulk drugs
3 and formulations. The key point is the 
increasing acceptance of India's formulations in the developed markets of the U.S. and 
E.U., which shows that Indian pharmaceutical firms have started adopting international 
standards in formulation manufacturing. Indian pharmaceutical exports, mainly of 
generics, are expected to increase five fold from $1.5 billion in 2002 when patents on 
brandname drugs worth $55 billion expire in the next few years (Kothari, 2003). The U.S. 
and the E.U. generic markets are likely to grow at 12-15 percent and 10-12 percent 
respectively in the next few years driven by concerns of rising health care costs. Also, 
since the price of generic drugs falls with the entry of new players, only cost-effective 
firms can break into the export markets. According to the Chairman of Morepen Labs, 
one of the fastest growing pharmaceutical companies in India, most of this cost 
differential stems from lower labour expenses which are about 80 percent less and lower 
infrastructure costs which are about 40 percent less (The Times of India, October 10, 
2001). In 2002-03, India exported nearly 40 percent of its total pharmaceutical output 
                                                 
2 Reverse-engineering is a method of using the functional aspects and underlying ideas of a product to 
develop a similar or identical product. 
3 Bulk drugs are the active chemical ingredients used to manufacture formulations or finished products. 
 with exports valued at nearly $2.6 billion. The major market is the U.S. that accounted 
for 17 percent of all pharmaceutical exports in 2002-03. Thus, Indian pharmaceutical 
exports have been able to penetrate the highly regulated markets of North America, 
Western Europe, Japan and Australia.  
Thus, technological activities are being undertaken in a growing number of firms and 
countries particularly from the South, along an increasingly differentiated technological 
frontier and at different stages of the product cycle. The main motivation of the paper is 
to test the product cycle theory in the presence of patent rights for a technology-intensive 
sector like pharmaceuticals. While many studies have been conducted on the relationship 
between technology and trade, most of them have been carried out for industrialized 
countries. Little attention has been focused on technological assimilation by developing 
countries and their capability to export technology-intensive products like 
pharmaceuticals in competitive international markets. However, with uniform laws for 
patent protection across all countries under TRIPs and particularly for process patents, 
the spotlight is on low-cost generic drug exports for off-patent drugs from developing 
countries like India. In addition, while earlier studies have used technology input 
indicators like R&D expenditures or S&T personnel for studying the relationship 
between technology and trade, this paper goes a step further and uses a technology output 
indicator given by foreign patent grants to acquire foreign patent rights (FPRs) by 
individual firms. It examines the role of FPRs on the export competitiveness of Indian 
pharmaceutical firms using a dynamic panel data model, and finds that after accounting 
for other firm characteristics like size and profitability, FPRs positively affect net exports. The rest of the paper is organized as follows: Section 2 briefly describes the 
theoretical underpinnings in the literature relating to international trade and technology. 
Section 3 discusses the literature on empirical studies of technology and export 
competitiveness. Section 4 describes the data and variables used in the study. Section 5 
outlines the model estimation procedure and section 6 lists the results of the study. 
Section 7 ends with the conclusion and policy suggestions.  
  
2. Theoretical literature 
In the neo-classical or Heckscher-Ohlin model of international trade, factor 
endowments are the key determinants of trade i.e. the comparative advantage of labour-
abundant countries lies in goods that require more labour. However, technology has no 
role to play as it is assumed to be universally and freely available to all. To account for 
technological change, various neo-technological models of international trade have been 
postulated (Posner, 1961; Vernon, 1966 and Krugman, 1979). Posner (1961) formulated 
the technology gap theory of international trade He treats technological change as a 
continuous process with (i) imitation lag or the lag between the introduction of a new 
technology and its adoption elsewhere and (ii) demand lag or the lag between the 
development of a new product and the emergence of its demand in other countries. He 
concludes that a continuous process of innovation would result in trade even between 
countries with similar factor endowments. Till the time producers from other countries 
learn to produce the new product due to either the time required for adapting the new 
technology or barriers such as patent protection, the demand in other countries will be filled by trade during the imitation lag. Thus, the innovator has to keep generating new 
innovations for sustained exports.  
Vernon’s (1966) product-cycle theory explains both trade and foreign direct 
investments (FDI). He identifies four stages in the life-cycle of a product: (1) innovation 
and introduction in the domestic market (2) saturation of the domestic market and search 
for foreign markets (3) foreign investments for the provision of the product in foreign 
markets (4) exports of the products from the foreign countries to the original home 
market. This theory says that new goods are more likely to be introduced in developed 
countries but will reach other countries as the product matures. In some cases, weak 
patent laws have resulted in the last two stages being appropriated by imitators from 
developing countries, rather than by FDI. As exports decline, the innovator firms start 
locating production facilities in developing countries for meeting the local demand and 
also for exporting back to developed countries. Thus, developed countries export new 
goods like brandname drugs and the developing countries export mature goods like 
generic drugs. Krugman (1979) formalized the product cycle model but assumed that 
technology “leaks” or the resources spent on imitation from developed to developing 
countries are exogenous. Northern firms introduce new products and earn high profits but 
these profits decline as the technology gets diffused and Southern firms engage in 
adaptive R&D to lower production costs. Thus, developing countries can play an 
important role in the international division of labour by specializing in the later stages of 
the product life cycle and eventually exporting hi-tech products in international markets.  
In their model of quality ladders and product cycles, Grossman and Helpman (1991) 
show that just as successful innovators in the North earn monopoly rents by innovating new products, successful imitators in the South earn rents because of cost advantages and 
the North-South production split is fixed due to an exogenously given patent term. They 
show that market shares fluctuate between innovators and imitators and that the steady-
state equilibrium is characterized by ongoing product upgradation and by product cycles 
where the average rates of imitation and innovation are constant. Glass (1997) develops a 
dynamic general equilibrium model of product cycle and shows that market penetration 
by developing countries initially occurs at low levels of technology and then reaches 
higher levels. The Southern markets penetrate the Northern markets by imitating previous 
quality levels and the Northern firms counter this by inventing higher quality levels. 
Moreover, she finds explanations for the increased penetration of East Asian countries 
into markets for high technology products on the basis of greater resources and weaker 
domestic patent rights but not R&D subsidies.  
On the whole, the recent theoretical and empirical literature on international trade has 
emphasized the role of technology and skills and, sometimes patent laws, in a country’s 
relative competitiveness. The neotechnology theories of trade emphasize the role of 
technology in explaining trade flows and explain how new product innovations by 
developed countries and process innovations for imitating those products by developing 
countries may lead to trade. As international markets become more competitive, 
technological ability protected by FPRs is likely to become increasingly important for all 
countries. We study the role of FPRs in the trade performance of Indian pharmaceutical 
firms at the mass production stage of the product cycle when the patent on brandname 
drugs expires and generic drugs are allowed to enter the market. In particular, we 
demonstrate that patents, which act as barriers to technological diffusion between the North and the South in the initial stages of the product cycle, can become the vehicle for 
greater market penetration by Southern countries in the later stages of the product cycle, 
to the extent that generic versions of previous brandname drugs also are covered by 
patent protection. 
 
3. Previous Studies 
Given the background of the neotechnology theories of trade, a number of studies 
have been undertaken to study market penetration by one country’s firms in other 
countries. It is worthwhile to study the relationship between technology and trade 
because it is the high quality products that are likely to cross borders and enter foreign 
markets in the early stages of the product cycle. The more technology-intensive products 
are expected to successfully cater to the tastes and demands of foreign consumers. These 
studies are based either on technology-input measures like R&D spending and scientific 
personnel employed or technology-output measures like patents and innovation counts.  
A number of sectoral studies have found a positive relationship between technology 
(measured by R&D spending, S&T personnel or patents) and exports (Keesing, 1967; 
Gruber  et al., 1967; Soete, 1981; Soete, 1987; Dosi et al., 1990; Greenhalgh,  1990; 
Buxton et al., 1991; van Hulst et al., 1991; Greenhalgh et al., 1994 and Greenhalgh et al., 
1996). Keesing (1967) and Gruber et al. (1967) were among the first to study the neo-
technology theories of trade and both of them found a high and positive correlation 
between U.S. exports and R&D. Soete (1981, 1987) studied 40 industries and found a 
positive relationship between patents and exports among technology-intensive industries. 
Sveikauskus (1983) studied the role of technology in U.S. foreign trade and concluded that it was R&D rather than capital or labour that was the main comparative advantage of 
industrialized countries. Fagerberg (1988) studied the growth in exports of 15 OECD 
countries and concluded that factors related to technology and capacity were more 
important in explaining the differences among countries than cost-competitiveness. Dosi 
et al. (1990) examined the relationship between the number of patents registered in the 
U.S. by 11 industrial countries and their exports and found a significant positive 
influence of the former on the latter. A study of five OECD countries conducted by van 
Hulst et al. (1991) found the link between technology and trade to be strongest in open 
export-oriented economies. Greenhalgh (1990), Greenhalgh et al. (1994) and Greenhalgh 
et al. (1996) found positive evidence of technology, measured by innovations and 
patents, in trade performance for the U.K. manufacturing industries. 
A similar conclusion of the positive relationship between R&D and exports also 
emerges from firm-level microeconometric studies (Willmore, 1992; Kumar and 
Siddharthan, 1994; Fagerberg, 1996; Wakelin, 1998; Bernard and Wagner, 1998; 
Lefebvre et al., 1998; Sterlacchini, 1999; Smith, 2001; Hasan and Raturi, 2003; Yang et 
al, 2004). Fagerberg (1996) found a positive association between technology measured 
by both R&D and patents, and export performance for a large number of industries, 
particularly chemicals (drugs, industrial chemicals, and plastics) and machinery 
industries. Lefebvre et al. (1998), studied small firms in Canada and found that R&D-
related capabilities such as a strong scientific and technical workforce, collaborative 
R&D and an R&D strategy aimed at launching new products, had a favourable impact on 
their export performance. Wakelin (1998) undertook a study of 320 U.K. firms from 
1988–1992 and found the export behaviour of innovating and non-innovating firms to be different. She found that while large innovative firms are likely to export, smaller 
innovative firms with one or two innovations are less likely to export and more likely to 
service the domestic market. Sterlacchini (1999) studied the innovative activities of small 
firms in Italy and found that activities such as design, engineering and pre-production 
developments were important in positively influencing exports. Smith (2001) analyzed 
the effect of foreign patents granted to U.S. firms on their exports, affiliate sales and 
licenses and found that FPRs did have a strong effect in expanding markets for U.S. 
manufacturers. 
However, while there exists a large body of literature regarding empirical studies on 
technology and trade for developed countries, only a few studies have been carried out 
for developing countries. Willmore (1992) focused on the role of MNCs in Brazil’s trade 
and found no evidence of R&D explaining either the probability of export or the export 
performance of exporters. Kumar and Siddharthan (1994) studied a panel of 13 Indian 
industries from 1988-1990 and found that a firm’s innovative activity does contribute to 
export competitiveness in low- and medium-technology industries but not in high-
technology industries. In another study of 11 Indian manufacturing industries from 1989-
1991, Hasan and Raturi (2003) find that R&D expenditure positively affects a firm’s 
entry into export markets but not its volume of exports which is determined more by size. 
But both these studies were for the period prior to liberalization and thus they may not 
capture the competitive forces unleashed due to foreign competition and hence the greater 
stress on R&D and exports by high-technology firms. 
 
 4. Data and variables 
4.1. Data sources 
The paper undertakes a microeconometric study of the trading behaviour of the Indian 
pharmaceutical industry in the light of policy changes and relates the same to a set of 
attributes that reflect the technological capability of firms proxied by foreign patent rights 
(FPRs). The study is based on a universe of 321 pharmaceutical companies (National 
Industrial Classification 2423) listed on the Bombay Stock Exchange and found in the 
Prowess database of the Centre for Monitoring Indian Economy (CMIE) for the period 
1991 to 2004 (years are financial years). The CMIE also provides data on ownership of 
firms.  
Further, firms belonging to the same ownership group were clubbed together so that 
the unit of study is a business entity i.e. the firm, its subsidiaries and mergers and 
amalgamations. After deleting the entries with missing observations and those with less 
than four years of data, the final sample was an unbalanced panel of 177 firms with 1866 
firm-year observations. The data for foreign patents granted to Indian pharmaceutical 
firms was obtained from the U.S. Patent and Trademark Office (USPTO) and the 
European Patent Office (EPO).  
 
4.2. Data description  
The average volume of net exports is to the tune to Rs 74.7 million at 1995 prices 
(see Table 1). However, the minimum and maximum values of net exports for the firms 
vary widely ranging from Rs –1024.5 million to Rs 12919.3 million at 1995 prices, 
resulting in a large standard deviation of Rs 579.9 million. The mean size of a firm is 1146 personnel. The distribution of foreign patents granted is also highly skewed since 
most firms do not apply for foreign patents. 
Table 2 gives the year-wise breakdown of Indian pharmaceutical firms with positive 
net exports and zero or negative net exports. Of the total 1866 observations, 839 
observations are for net exporters and 1027 observations are for zero or net importers. 
Firms are divided into three types: continuing net exporters or net importers, switchers 
between net exporters and net importers and entrants into the dataset after 1991 as net 
exporters or net importers. From Table 2, it can be deduced that the yearly rate of 
switching between net exporters and net importers is substantial.  
 
4.3. Variables used in the study 
  Following Greenhalgh (1990), Greenhalgh et al. (1994) and Greenhalgh et al. 
(1996), the dependent variable used in the study is net exports (exports less imports) that 
provides a broad indicator of the relative success or failure for testing the comparative 
advantage of firms. This is because we wish to investigate the effects of innovation in the 
pharmaceutical industry, which has witnessed significant growth in intra-firm trade. 
Since imports usually consist of inputs, while exports include both bulk drugs and 
formulations, the dependent variable can be interpreted as the ‘domestic value added’ by 
Indian pharmaceutical firms. This domestic value added measured in million rupees is 
deflated by the unit price index of exports
4 for ‘chemicals and related products’ obtained 
                                                 
4 The unit price index number is calculated by Paasche’s formula and it compares trade in the current 








=  where n denotes the current period and b 
the base period. from the Handbook of Statistics on Indian Economy for various years, published by the 
Reserve Bank of India (RBI).  
  To examine the role of sunk costs in entering foreign markets, we use the lag of 
net exports as a regressor in the export function. We expect a positive effect of lagged 
exports since the sunk costs incurred for gathering information, marketing and 
distribution, evaluating tastes and preferences in the past year are likely to aid exports in 
the current year (see Robert and Tybout, 1997). Thus, we hypothesize that once a generic 
drug that is made in India enters a foreign market, it is able to retain that market for 
sometime. 
In order to assess the role of technology in trade, we study the number of foreign 
patents granted to Indian pharmaceutical firms in the U.S. or E.U. since they are the 
major trading partners of India. While there is no universally acceptable method of 
measuring innovative activities, patent statistics offer a comprehensive picture of 
technological activity since patent offices have a detailed and complete record of 
innovative activity in any industry. Foreign patents are a satisfactory indicator of ongoing 
innovative activities and are fewer and of better quality than domestic patents since 
innovative firms are more discriminating and selective in filing patents in foreign 
countries owing to the higher costs involved.   
Process patents are important for generic manufacturers to encourage them to invest in 
new production processes that lower costs of production. We expect a significant effect 
of FPRs on exports since patents protect the innovations of firms from imitation by other 
firms servicing foreign markets. In fact, the need to secure an American or European 
patent arises because an Indian firm servicing the U.S. or E.U. markets is not protected by the Indian patent law. Thus, there may be a correlation between FPRs and exports 
such that foreign patents may not be strictly exogenous. 
   Size of a firm is measured by employment of personnel. Size is included as an 
explanatory variable because there exist considerable entry costs of selling goods in 
foreign markets such as transportation costs, distribution costs, information costs or 
production costs to suit foreign tastes. These act to a greater or lesser extent as entry 
barriers that smaller firms may find difficult to overcome. Thus, given a sample of firms 
within an industry, the larger and more innovative firms are more likely to become net 
exporters. We also study the relationship between the square of size and export 
performance to account for the possible non-linearity in the relationship. The CMIE 
database does not report the number of employees in a firm, so the series on labor is 
generated by dividing the data on firm-wise wages and salaries by the wage rate. The 
wage rate, in turn, is derived from the ratio of total emoluments to the number of 
employees for the pharmaceutical industry as a whole, obtained from various issues of 
the  Annual Survey of Industries,  Summary Results Factory Sector published by the 
Central Statistical Organization (CSO).  
  Profitability is measured as net profits after tax in million rupees deflated by the 
GDP deflator with base year 1995 given in the International Financial Statistics for 
various years published by the International Monetary Fund. It is expected to positively 
affect exports to capture tax concessions granted by the Government of India for export 
activity since it is the net profit after deducting corporate tax. Further, profit-making 
firms are more likely to undertake risks inherent in exploring foreign markets compared 
to loss-making firms. Thus, it is likely that profits are correlated with exports in any given year leading to the problem of endogeneity, which is taken care of by using 
instrumental variables in the estimation procedure. 
 
5. Methodology 
We examine the effect of technology and innovations on net exports by estimating the 
export function given other firm characteristics like size, size squared and profitability. 
We estimate the net exports function using ordinary least squares (OLS) and instrumental 
variables (IV) estimation under the generalized methods of moments (GMM) framework. 
 
5.1. OLS with fixed effects 
Consider the following dynamic model where the dependent variable, net exports , 
is a linear function of the lagged net exports and the explanatory variables where i = 
1,..…N indexes firms and t = 1,….T indexes time periods: 
it y
it X
  it i it it it u X y y + + + = − ε β γ 1                                                      (5.1) 
In equation (5.1), β  represents the vector of parameters to be estimated,   
represents the explanatory variables like size, profitability, foreign patent grants and time 
dummies,   is the random error and 
it X
it u i ε is the unobserved firm-specific heterogeneity. 
We include time dummies for the years 1991-2004 for all model specifications to pick up 
any annual exchange rate effects in the data as well as other macroeconomic policy 
changes like the setting up of the WTO and harmonization of patent laws across 
countries.  The firm-specific effect  i ε , such as managerial ability or export focus of any firm, is 
invariant over time and is unobservable. Such an unobservable fixed effect is potentially 
correlated with the other regressors. Given that T  is fixed and  ∞ → N , the estimates of 
β  are consistent but the estimates of the fixed effects are not consistent since the number 
of these parameters increases as N increases resulting in a large loss of the degrees of 
freedom. If the fixed effects are not controlled for in the estimation, then inconsistent 
estimates can result due to an omitted variable bias. These firm-specific effects can be 
eliminated by either first-differencing or mean-differencing equation (5.1). While the first 
difference OLS model produces consistent estimates of β , the error term becomes a 
moving-average and may create problems in estimation. Thus, we use the alternative 
procedure to eliminate the fixed effects by taking the deviations from the mean given by:  
      ) ( ) ( ) ( ) ( 1 1 it it it it it it it it u u X X y y y y − + − + − = − − − β γ                                    (5.2) 
However, with mean-differencing,  1 − it y  gets correlated with the error term  ) ( it it u u −  
even if   is itself not serially correlated. The correlation between the lagged dependent 
variable and the error term makes the estimate for 
it u
γ  biased such that OLS provides 
biased estimates as compared to IV regression owing to endogeneity of the regressors. 
Further, if the error terms are correlated within groups but not correlated across groups, 
then the estimates for IV regression are consistent not their standard errors, as in the 
presence of heteroskedasticity. In the presence of heteroskedasticity of unknown form, IV 
regression generates consistent but inefficient estimates, thus necessitating the use of the 
dynamic panel GMM estimation (see Baum et al., 2003). 
 
 5.2. GMM estimation 
In the export function, foreign patents and profits are not strictly exogeneous to 
exports and we have to account for this endogeneity problem. The endogeneity problem 
arises from using foreign patents as an explanatory variable because, in general, foreign 
patenting is itself undertaken to protect export markets. Similarly, higher profits may 
promote higher exports due to the availability of resources. The GMM model relaxes the 
strict exogeneity assumption of the regressors and uses the orthogonality conditions for 
efficient estimation even in the presence of heteroskedasticity (Baum et al., 2003).  
  Owing to the problem of endogeneity,  0 ) ( ≠ it itu X E . For GMM estimation, 
regressors are partitioned into two subsets of endogenous and exogenous regressors 
 where the   regressors of   are endogenous and the remaining  [ 2 1X X ] 1 K 1 X 1 K K −  
regressors of   are exogenous. The set of instrumental variables Z is of the order  2 X L N ×  
and is assumed to be exogenous 0 ) ( = it itu Z E . The order condition for the identification 
of the equation requires that the excluded instruments be at least as many as endogenous 
variables. If  K L = , the equation is “exactly identified” and if  K L > , it is 
“overidentified”. The L instruments produce a set of L moment conditions given by: 
            , where  it it it u Z g ˆ ) ˆ (
' = β 1 × = L git                         (5.3) 
The exogeneity of the instruments implies that there are L orthogonality or moment 
conditions such that  0 )) ( ( = β it g E  at the true value of β . 
The GMM-IV estimation proceeds by mean-differencing the equation and then using 
lagged levels of the series as instruments for the predetermined and endogenous variables 
in the differenced equations (Arellano and Bond, 1991). Instruments should be valid and 
relevant such that they are correlated with the regressors but are orthogonal to the errors. While  and   are correlated with the firm-specific effects  it y it X i ε , their differenced 
transformations are not correlated with  i ε , permitting lagged size and profits to be used 
as instruments in the levels equations. The relative advantage of GMM lies in its efficient 
use of the number of instruments generated for the endogenous regressors. Further, the 
number of instruments increases as the panel progresses so that an increasing number of 
instruments become available which increases the efficiency of the estimation. 
However, the standard GMM estimator may lead to finite sample bias. To improve 
upon the standard GMM estimator, we use the “system” GMM estimator (GMM-SYS) 
such that the lagged differences are used as instruments for equations in levels together 
with the lagged levels as instruments in the differenced equations (Arellano and Bover, 
1995; Blundell and Bond, 1998 and Blundell et al. 2000). The GMM estimates are not 
biased by unobserved fixed effects and are consistent even in the presence of 
measurement error. For the validity of the instruments, we use the Sargan test for 
overidentifying restrictions.  
 
6. Empirical results 
Table 3 shows the parameter estimates for the export performance of Indian 
pharmaceuticam firms using different models: Least squares with fixed effects (OLS-FE) 
in column 1; Least squares with mean-differencing (OLS-DIFF) in column 2; 
instrumental variable GMM (GMM-IV) in column 3 and system-GMM (GMM-SYS) in 
column 4. A Hausman test of fixed versus random effects supports the fixed effects 
model and thus we mean-difference the net exports equation to take care of the fixed 
effects. We conduct the Davidson-MacKinnon test of the exogeneity of regressors to check whether the fixed-effect OLS or IV regression is the appropriate regression model. 
A rejection of the test statistic, under the null of no deleterious effects on OLS estimates 
due to endogeneity of the regressors, suggests that the OLS-FE model is inappropriate. 
The Pagan-Hall test for the presence of heteroskedasticity using levels and cross products 
of all the instruments provides evidence of heteroskedasticity. Thus, we opt for IV 
estimation under the GMM framework instead of the standard IV estimation since GMM 
estimates are consistent in the presence of heteroskedasticity. 
  Looking at the results for past year’s net exports, we find that the parameter 
estimates are positive and significant across the different regression models. Thus, an 
excess of exports over imports in the previous year has a favourable impact on net 
exports in the current year, most likely due to past sunk costs like information regarding 
tastes, distribution and marketing channels, and after-sales services. On successful 
penetration of foreign markets, a given firm is likely to remain there for sometime. 
Further, it implies that any domestic value added in the previous year helps the firms in 
value addition over their imports in the current year also. 
Regarding size, the results show that the size of the firm, proxied by the labour 
employed, has a positive effect on net exports in all the models. This shows economies of 
scale in production and marketing for Indian pharmaceutical firms. The GMM-SYS 
estimates show that an additional employee raises net exports by Rs 927,000. However, 
the square of size is negative and significant, indicating a non-linear relationship between 
size and net exports. Thus, size has a threshold effect on exports so that after reaching a 
certain level, further increases in size do not positively affect entry into export markets. 
On the one hand, exporting may be beyond the capacity of small firms, but on the other, very large firms may not want to venture into export markets given that there is a large 
domestic market in India itself. Figure 1 plots the size against a function
5 of size and size 
squared. From the graph, we can discern that the turning point occurs when the firm 
reaches the employment level of around 1700 personnel, which is higher than the average 
size of Indian pharmaceutical firms.  
Net profits of a firm also have a positive and significant effect on export behaviour. A 
profitable firm can successfully penetrate foreign markets since huge resources are 
required to maintain delivery and after-sales services. It also suggests that tax 
concessions act as important incentives for exports.  
  Finally, foreign patent grants have a significant and positive effect on net exports 
in all the models. Thus, technology proxied by FPRs does have a favourable impact on 
exports as the product cycle unfolds and firms from developing countries enter the export 
market at the stage of standardization such as generic pharmaceuticals. According to the 
GMM-SYS estimates, an additional patent filed abroad has the potential to raise net 
exports by Rs 142,000. Thus, developing countries like India can compete in the global 
market based on process innovations and cost advantages. In particular, the 
pharmaceutical industry in India is fortunate in that it has a history of manufacturing 
generic drugs by reverse-engineering and now it is an opportune time for the industry to 
exploit its potential for process innovations in the world markets owing to the 
harmonization of patent laws due to TRIPs. 
 
 
                                                 
5 The graph plots size against 0.927size-0.027size
2 by using the parameter estimates from the preferred 
GMM-SYS model. 7. Conclusion 
The paper finds that the export market is substantially dynamic and the implications of 
the results for government policy are immense. The results show that innovations do not 
merely reflect the extent of technological opportunity but are a strategic tool for gaining 
market share even in world markets. Our findings suggest that an innovative environment 
is likely to encourage exports since FPRs increase net exports, at least in the case of 
Indian pharmaceutical firms. Thus, it is an opportune time for developing countries like 
India to diversify their exports to exploit the “generic niche” in international markets.  
Further, given that size is a crucial factor for overcoming the sunk costs of entering 
export markets and Indian manufacturing industry is dominated by small firms, there is a 
role for the government to help these firms in international markets. The government 
could introduce policies designed for small firms to provide technical support, easy 
credit, marketing and distribution channels and information regarding foreign markets. A 
potential area for future research is the role of FDI outflows on exports since Indian firms 
have recently started undertaking huge investments abroad. It would be worthwhile to 
examine whether the relationship FDI outflows and exports is complementary or the 














Aoki,  R. and Prusa, T. J., 1993. International standards for intellectual property 
protection and R&D incentives. Journal of International Economics 35, 251-273. 
Aquino, A., 1981. Changes over time in the pattern of comparative advantage in 
manufactured goods. European Economic Review 15, 41–62. 
Arellano, M. and Bond, S., 1991. Some tests of Specification for panel data: Monte Carlo 
evidence and an application to employment equation. Review of Economic Studies 58, 
277-297. 
Arellano, M. and Bover, O., 1995. Another look at the instrumental variable estimation of 
error-components models. Journal of Econometrics  68, 29-52. 
Blundell, R. and Bond, S., 1998. Initial conditions and moment restrictions in dynamic 
panel data models. Journal of Econometrics 87, 115-143. 
Blundell, R., Bond S. and Windmeijer, F., 2000. Estimation in dynamic panel data 
models: Improving on the performance of the standard GMM estimator. In: Baltagi B. 
H. (Ed) Advances in econometrics (vol 15) Nonstationary panels, panel cointegration, 
and dynamic panels, Elsevier Science, College Station, Texas, 53-91. 
Baldwin, R. E., 1979. Determinants of trade and foreign investment: Further evidence. 
Review of Economics and Statistics 61, 40-48. 
Bernard, A. B. and Jensen, J. B., 1999. Exceptional export performance: Cause, effect or 
both? Journal of International Economics 47, 1-25. 
Baum, C. F., Schaffer, M. E. and Stillman, S., 2003. Instrumental variables and GMM: 
Estimation and testing.  Stata Journal  3, 1-31. 
Bernard, A. B. and Wagner, J., 1997. Exports and success in German manufacturing. 
Weltwirtschaftliches Archiv 133, 134-157. 
Bernard, A. B. and Wagner, J., 2001 Export entry and exit by German firms. 
Weltwirtschaftliches Archiv 137, 105-123. 
Buxton, T., Mayes, D. and Murfin, A., 1991. U.K. trade performance and R&D. 
Economics of Innovation and New Technology 1, 243–256. 
Deardorf, A., 1984. Testing trade theories and predicting trade flows. In: Jones, R. and 
Kenen, P. (Eds) Handbook of international economics, vol I. North Holland, 
Amsterdam. 
Dosi, G., Pavitt, K. and Soete, L., 1990. The economics of technical change and 
international trade, Harvester Wheatsheaf, Hemel Hempstead. 
Fagerberg, J., 1988. International competitiveness. Economic Journal 98, 355-374. 
Fagerberg, J., 1996. Technology and competitiveness. Oxford Review of Economic 
Policy 12, 39-51. 
Glass, A. J. 1997. Product cycles and market penetration. International Economic Review 
38, 865-891. 
Greenhalgh, C., 1990. Innovation and trade performance in the United Kingdom. 
Economic Journal 100, 105-118. 
Greenhalgh, C., Taylor, P. and Wilson, R., 1994. Innovation and export volumes and 
prices—A disaggregated study. Oxford Economic Papers  46, 102–34. 
Greenhalgh, C., Mavrotas, G. and Wilson, R., 1996. Intellectual property, technological 
advantage and trade performance of UK manufacturing industries. Applied Economics 
28, 9-19. Grossman, G. M. and Helpman, E., 1991. Quality ladders and product cycles. Quarterly 
Journal of Economics 106, 557-586. 
Gruber, W., Mehta, D. and Vernon, R., 1967. The R&D Factor in international trade and 
international investment of United States industries. Journal of Political Economy 75, 
20-37.  
Hasan, R. and Raturi, M., 2003. Does investing in technology affect exports? Evidence 
from Indian firms. Review of Development Economics 7, 279-293.  
Hirsch, S., 1976. An international trade and investment theory of the firm. Oxford 
Economic Papers 28, 258-270. 
Hufbauer, G. C., 1970. The Impact of National Characteristics and Technology in the 
Commodity Composition of Trade in Manufactured Goods. In: Vernon R (Ed), The 
technology factor in international trade, Columbia University Press, New York, p. 
145-231. 
Hughes, K., 1986a. Exports and innovation: A simultaneous model. European Economic 
Review  30, 383-399. 
Hughes, K., 1986b. Exports and technology. Cambridge University Press, Cambridge.  
Kothari, A., 2003. Facets of Indian Pharma R&D, India Equity Research, Paper presented 
at Mumbai, April 2003. 
Krugman, P., 1979. A model of innovation, technology transfer and the world 
distribution of income. Journal of Political Economy 87, 253-266. 
Kumar, N. and Siddharthan, N. S., 1994. Technology, firm size and export behaviour in 
developing countries: The case of Indian enterprises. Journal of Development Studies 
31, 289-302. 
Lall, S. 1998. Exports of manufactures by developing countries: Emerging patterns of 
trade and location. Oxford Review of Economic Policy 14, 54-73. 
Lefebvre, E., Lefebvre, L. A. and Bourgault, M., 1998. R&D related capabilities as 
determinants of export performance. Small Business Economics 10, 365–377. 
Pavitt, K., 1982. R&D, patenting and innovative activities: A statistical exploration. 
Research Policy 11, 33–51. 
Posner, M. V., 1961. International trade and technical change. Oxford Economic Papers 
13, 11-37. 
Robert, M. and Tybout, J., 1997. The decision to export in Columbia: An empirical 
model of entry with sunk cost.  American Economic Review 87, 545–564. 
Segerstrom, P. S., Ananth, T. C. A. and Dinopoulos, E. A., 1990. Schumpeterian model 
of the product life-cycle. American Economic Review 80, 1077-1091. 
Smith, P. J., 2001. How do foreign patent rights affect U.S. exports, affiliate sales, and 
licenses? Journal of International Economics 55, 411–439. 
Soete, L., 1987. The impact of technological innovation on international trade patterns: 
The evidence reconsidered. Research Policy 16, 101-130. 
Sterlacchini, A., 1999. Do innovative activities matter to small firms in non-R&D-
intensive industries? An application to export performance. Research Policy 28; 819–
832. 
Sterlacchini, A., 2001. The determinants of export performance: A firm-level study of 
Italian manufacturing. Weltwirtschaftliches Archiv 137, 450-472. 
Sveikauskas, L., 1983. Science and technology in United States foreign trade. Economic 
Journal 93, 542–54. Van Hulst, N., Mulder, R. and. Soete, L. L. G., 1991. Exports and technology in 
manufacturing industry. Weltwirtschaftliches Archiv 127, 246-264. 
Vernon, R., 1966. International investment and international trade in the product cycle. 
Quarterly Journal of Economics 80, 190-207. 
Vernon, R. (Ed), 1977. The technology factor in international trade. National Bureau of 
Economic Research, New York. 
Wakelin, K., 1998. Innovation and export behaviour at the firm level. Research Policy 
26, 829-841. 
Yang, C. H., Chen, J. R. and Chuang, W.B., 2004. Technology and export decision. 
Small Business Economics 22; 349-364.  
Zimmerman, C. S. and Dunlop L. J., 1994. Overview: Intellectual Property- The New 
Global Currency. In: Simensky, M. and Bryer, L. G. (Ed) The role of intellectual 






























 Table 1 
Descriptive statistics of key variables 
Variable Mean  Std  Dev  Min  Max 
Net exports 
(Rs million, 1995 prices) 
74.7 579.9  -1024.5  12919.3 
Size 1146  2345  10  29228 
Net profits 
(Rs million, 1995 prices) 
73.9 277.1  -1433.7  5133.4 















 Table 2 
Switching between net exporters and net importers, 1991-2004 
Number of net exporters in  Number of net importers in  Year 
t  t, t-1  t, not t-1  enter, t  t  t, t-1  t, not t-1  enter, t 
1991 15        38       
1992 22  10  9  3  44  30  5  9 
1993 23  15  5  3  60  39  7  14 
1994 40  19  11  10  70  48  4  18 
1995 46  34  6  6  91  65  6  20 
1996 65  43  17  5  92  74  3  15 
1997 79  57  20  2  86  72  8  6 
1998 74  64  10  0  98  79  16  3 
1999 82  66  14  2  89  79  7  3 
2000 82  70  12  0  88  74  13  1 
2001 83  70  12  1  81  71  9  1 
2002 81  71  10  0  75  65  10  0 
2003 80  69  11  0  67  60  7  0 
2004 67  60  7  0  48  42  6  0 




 Table 3 




















































Hausman test  246.45 
[0.0] 





   
Pagan-Hall test 
 
   380.168 
[0.0] 
 
Wald test ( ) 


















Year dummies  Yes 
 
Yes Yes Yes 
Notes: Robust t statistics are given in parentheses and P-values in square brackets. ***, 
**, * denote that the coefficients are statistically different from zero at the 1-, 5- and 10-
percent levels, respectively.  
1. The reported estimates for GMM are based on the two-step GMM estimator. 
2. Davidson-MacKinnon test is an F-test of exogeneity of regressors for a fixed-effect IV 
estimation where the null hypothesis is that the estimates from OLS-FE are consistent.  
3. Pagan-Hall test is a  test where the null hypothesis is that the disturbance is 
homoskedastic. 
2 χ
4. Sargan test is a test for overidentifying restrictions, asymptotically distributed, 
under the null of instrument validity. 
2 χ
5. AR(1) and AR(2) are tests for first-order and second-order serial correlation in the 
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